Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

NEMKOV, MELVIN

NPI: 1649325283 · CHELMSFORD, MA 01824 · Internal Medicine Physician · NPI assigned 01/24/2007

$582K
Total Medicaid Paid
11,107
Total Claims
5,011
Beneficiaries
7
Codes Billed
2018-01
First Month
2023-06
Last Month

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 2,457 $110K
2019 2,230 $99K
2020 2,465 $131K
2021 2,138 $127K
2022 1,266 $81K
2023 551 $34K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 4,750 1,910 $225K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 2,664 1,300 $147K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2,108 939 $126K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 777 406 $74K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity 363 248 $6K
81025 421 194 $3K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 24 14 $2K